Applied DNA Sciences, Inc.
APDN
$0.1296
$0.00131.01%
| Weiss Ratings | APDN - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Very Weak | |||
| Risk Index | Weak | |||
| Risk Grade | D- | |||
| Reward Grade | E | |||
| Rating Factors | APDN - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | -- | |||
| Growth Index | Weak | |||
| Efficiency Index | Very Weak | |||
| Solvency Index | Excellent | |||
| Total Return Index | Very Weak | |||
| Volatility Index | Weak | |||
| Beta / Standard Deviation | APDN - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | 3.82 | |||
| Price History | APDN - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | -10.56% | |||
| 30-Day Total Return | -26.78% | |||
| 60-Day Total Return | -19.35% | |||
| 90-Day Total Return | -62.77% | |||
| Year to Date Total Return | -47.53% | |||
| 1-Year Total Return | -98.85% | |||
| 2-Year Total Return | -99.49% | |||
| 3-Year Total Return | -99.70% | |||
| 5-Year Total Return | -99.86% | |||
| 52-Week High % Change | -98.91% | |||
| 52-Week Low % Change | 6.56% | |||
| Price | APDN - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $11.76 | |||
| 52-Week Low Price | $0.12 | |||
| 52-Week Low Price (Date) | Dec 13, 2024 | |||
| 52-Week High Price (Date) | Mar 12, 2024 | |||
| Valuation | APDN - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | 7.08M | |||
| Enterprise Value | -1.81M | |||
| Price/Earnings (TTM) | -- | |||
| Earnings Per Share (TTM) | -5.72 | |||
| Earnings Per Share Growth | -47.62% | |||
| Price/Earnings To Growth | -- | |||
| Price/Sales (TTM) | 1.08 | |||
| Price/Book (Q) | 0.54 | |||
| Enterprise Value/Revenue (TTM) | -0.48 | |||
| Price | $0.13 | |||
| Enterprise Value/EBITDA (TTM) | 0.14 | |||
| Enterprise Value/EBIT | 0.14 | |||
| Market Cap Category | Nano Cap | |||
| Dividends and Shares | APDN - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 31.52M | |||
| Dividend Yield | -- | |||
| Div. Per Share (Most Recent) | -- | |||
| Dividend Per Share (TTM) | -- | |||
| Payout Ratio (TTM) | -- | |||
| Dividend Per Share (Most Recent) | -- | |||
| Company Info | APDN - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | 631 240 8800 | |||
| Address | 50 Health Sciences Drive Stony Brook, NY 11790 | |||
| Website | www.adnas.com | |||
| Country | United States | |||
| Year Founded | 1983 | |||
| Profitability | APDN - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | -353.23% | |||
| Profit Margin | -228.18% | |||
| Management Effectiveness | APDN - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | -63.75% | |||
| Return on Equity | -- | |||
| Income Statement | APDN - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | 3.74M | |||
| Total Revenue (TTM) | 3.74M | |||
| Revenue Per Share | $0.12 | |||
| Gross Profit (TTM) | 1.47M | |||
| EBITDA (TTM) | -12.74M | |||
| EBIT (TTM) | -13.20M | |||
| Net Income (TTM) | -8.53M | |||
| Net Income Avl. to Common (TTM) | -8.53M | |||
| Total Revenue Growth (Q YOY) | 34.27% | |||
| Earnings Growth (Q YOY) | -136.11% | |||
| EPS Diluted (TTM) | -5.72 | |||
| EPS Diluted Growth (Q YOY) | 67.82% | |||
| Balance Sheet | APDN - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | 9.29M | |||
| Cash Per Share (Q) | $0.29 | |||
| Total Current Assets (Q) | 11.28M | |||
| Total Preferred Equity (Q) | -- | |||
| Total Equity (Q) | 12.55M | |||
| Current Ratio (Q) | 4.725 | |||
| Book Value Per Share (Q) | $0.24 | |||
| Total Assets (Q) | 15.97M | |||
| Total Current Liabilities (Q) | 2.39M | |||
| Total Debt (Q) | 607.30K | |||
| Total Liabilities (Q) | 3.42M | |||
| Total Common Equity (Q) | 12.75M | |||
| Cash Flow | APDN - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | -524.80K | |||
| Cash from Financing (TTM) | 19.74M | |||
| Net Change in Cash (TTM) | 5.94M | |||
| Levered Free Cash Flow (TTM) | -9.26M | |||
| Cash from Operations (TTM) | -13.28M | |||
